GROWTH
Top line decelerating.
+12.8% YoY versus +39.9% prior. 3y CAGR +23.7%.
+12.8%
Corcept Therapeutics Incorporated CORT
Healthcare · Market Cap: $8.6B
$79.91▼ 1.84 (2.25%)
Fundamentals as of 2025-12-31
We use cookies
MainRatios uses cookies for essential site functions. With your consent, we also use analytics cookies including session replay sampling (PostHog, Google Analytics) and advertising cookies (Google AdSense). You can reject non-essential cookies, including the "sale" or sharing of personal information under CCPA, and you may withdraw consent at any time (GDPR). See our Privacy Policy for details.
Healthcare · Market Cap: $8.6B
Fundamentals as of 2025-12-31
All analysis on this page is for educational purposes only and does not constitute financial advice. Fair values are model-based estimates. Always do your own research.
Bottom line: CORT currently has no legendary investor models qualifying — see /stock/CORT/valuation for the per-model breakdown, but earns a D sector grade (44/100) in Healthcare. Use the per-tab analysis to form your own view. Drill into the valuation breakdown and sector ranking for the full picture.
The Question
+12.8% YoY versus +39.9% prior. 3y CAGR +23.7%.
+12.8%Net margin 13.1% versus 20.7% prior (−7.6pp). Operating 5.9%.
13.1%P/E 207.5x — 425% above the 5y median of 39.5x. Forward 136.5x hints at EPS expansion next year.
207.5xInvestor verdicts vary by methodology. Full breakdown by investor and signal is in the valuation tab.
CORT's earnings calendar and history are tracked in the financials tab. Specific dates depend on company-published guidance.
CORT is in the Healthcare sector. Sector ranking and peer comparison are in the sector tab.
0 of 6 legendary investor models rate CORT a BUY. Fair value estimates and full investor breakdown are in the valuation tab.
Corcept Therapeutics Incorporated's fair value depends on which model you trust. See the per-investor fair-value table in the valuation tab.
CORT trades at 51.7x earnings. Sector context and per-investor signals are in the valuation tab
Yes — Corcept Therapeutics Incorporated's 15.4% ROE ranks above the S&P 500 median, and D/E 0.29 stays within healthy bounds.
Financial story
Yes — Corcept Therapeutics Incorporated's 15.4% ROE shows strong capital efficiency, and its 0.29 debt-to-equity stays within healthy bounds.
How does CORT compare?
See exactly where CORT ranks
Sign in to unlock the full sector ranking — free.
Sign in to see the rankingCORT sits at #78 in Healthcare with a D grade (44/100).
